CYP2C19 Genotype and Pharmacokinetics of Three Proton Pump Inhibitors in Healthy Subjects

[1]  M. Kasuga,et al.  Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. , 1999, Journal of gastroenterology.

[2]  Y. Tanigawara,et al.  CYP2C19 genotype–related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori , 1999 .

[3]  T. Ishizaki,et al.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[4]  T. Humphries,et al.  Review article: drug interactions with agents used to treat acid‐related diseases , 1999, Alimentary pharmacology & therapeutics.

[5]  R. Spiller,et al.  The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. , 1999, Gastroenterology.

[6]  T Ishizaki,et al.  CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. , 1998, Clinical pharmacology and therapeutics.

[7]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.

[8]  T. Ishizaki,et al.  Metabolic disposition of lansoprazole in relation to the S‐mephenytoin 4′‐hydroxylation phenotype status , 1997, Clinical pharmacology and therapeutics.

[9]  R. Spiller,et al.  Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. , 1996, Gastroenterology.

[10]  S. Higuchi,et al.  Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects , 1996 .

[11]  S. Binkley,et al.  Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. , 1996, Pharmacogenetics.

[12]  Kaoru Kobayashi,et al.  Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status , 1995, Clinical pharmacology and therapeutics.

[13]  G. Granneman,et al.  Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. , 1995, Journal of chromatography. B, Biomedical applications.

[14]  L. Pickle,et al.  The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study , 1995, Clinical pharmacology and therapeutics.

[15]  L. Bertilsson,et al.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. , 1995, British journal of clinical pharmacology.

[16]  M. Relling,et al.  Nomenclature for N-acetyltransferases. , 1995, Pharmacogenetics.

[17]  C. Bonfils,et al.  Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.

[18]  O vanRensburg,et al.  Helicobacter pylori in peptic ulcer disease. , 2004, Delaware medical journal.

[19]  G. Kahlmeter,et al.  Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. , 1994, The Journal of antimicrobial chemotherapy.

[20]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[21]  M. Kayano,et al.  Determination of a new H(+)-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography. , 1994, Journal of chromatography. B, Biomedical applications.

[22]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[23]  Fred E. Silverstein,et al.  Helicobacter pylori in peptic ulcer disease. , 1994, NIH consensus statement.

[24]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[25]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. , 1994, British journal of clinical pharmacology.

[26]  T. Andersson,et al.  Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. , 1994, Therapeutic drug monitoring.

[27]  L. Hansson,et al.  Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. , 1993, Gastroenterology.

[28]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.

[29]  N. Lam,et al.  Helicobacter pylori and peptic ulcer disease. , 1993, Clinical pharmacy.

[30]  Kaoru Kobayashi,et al.  Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. , 1992, Journal of chromatography.

[31]  K. Chiba,et al.  Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. , 1992, The Journal of pharmacology and experimental therapeutics.

[32]  P D Klein,et al.  Effect of Treatment of Helicobacter pylori Infection on the Long-term Recurrence of Gastric or Duodenal Ulcer , 1992, Annals of Internal Medicine.

[33]  T. Yashiki,et al.  High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. , 1991, Journal of chromatography.

[34]  G. Friedman,et al.  Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.

[35]  M. Quina,et al.  Omeprazole in the treatment of peptic ulcers resistant to H2‐receptor antagonist , 1990, Alimentary pharmacology & therapeutics.